Ceftolozane and Tazobactam
Brand names: Zerbaxa · Active ingredient: Ceftolozane Sulfate, Tazobactam Sodium
In short: ZERBAXA used in combination with metronidazole is indicated for the treatment of adult and pediatric patients (at least 32 weeks gestational age) with complicated intra-abdominal infections (cIAI) caused by the following susceptible Gram-negative and Gram-positive microorganisms: Enterobacter cloaca
What is Ceftolozane and Tazobactam used for?
ZERBAXA used in combination with metronidazole is indicated for the treatment of adult and pediatric patients (at least 32 weeks gestational age) with complicated intra-abdominal infections (cIAI) caused by the following susceptible Gram-negative and Gram-positive microorganisms: Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, and Streptococcus salivarius.
ZERBAXA is indicated for the treatment of adult and pediatric patients (at least 32 weeks gestational age) with complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Pseudomonas aeruginosa.
ZERBAXA is indicated for the treatment of adult and pediatric patients (at least 32 weeks gestational age) with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by the following susceptible Gram-negative microorganisms: Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Serratia marcescens. …
Ceftolozane and Tazobactam dosage
The recommended dosage of ZERBAXA in adult patients is 1.5 gram (g) (ceftolozane 1 g and tazobactam 0.5 g) for cIAI and cUTI and 3 g (ceftolozane 2 g and tazobactam 1 g) for HABP/VABP administered every 8 hours by intravenous infusion over 1 hour. As shown in Table 1, guide the duration of therapy by the severity and site of infection and the patient’s clinical and bacteriological progress. For the treatment of cIAI, administer metronidazole concurrently. See Table 3 for the recommended dosage in adult patients with renal impairment,
Infection | Dose | Frequency | Infusion Time | Duration of Treatment
Complicated Intra-abdominal InfectionsUsed in conjunction with metronidazole 500 mg intravenously every 8 hours | ZERBAXA 1.5 gProvides 1 g ceftolozane and 0.5 g tazobactam | Every 8 Hours | 1 hour | 4 to 14 days
Complicated Urinary Tract Infections, Including Pyelonephritis | ZERBAXA 1.5 g | Every 8 Hours | 1 hour | 7 days
Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia | ZERBAXA 3 gProvides 2 g ceftolozane and 1 g tazobactam | Every 8 Hours | 1 hour | 8 to 14 days
The recommended dosage regimen for ZERBAXA in pediatric patients (at least 32 weeks gestational age) is described in Table 2. As shown in Table 2, guide the duration of therapy by the severity and site of infection and the patient’s clinical and bacteriological progress.
For the treatment of cIAI, administer metronidazole concurrently. See Table 4 for the recommended dosage in pediatric patients with renal impairment .
Infection | Age Range | Dose | Frequency | Infusion time | Duration of treatment
Complicated Intra-abdominal InfectionsUsed in conjunction with metronidazole. | All pediatric patients (at least 32 weeks gestational age) | ZERBAXA 30 mg/kgProvides 20 mg/kg ceftolozane and 10 mg/kg tazobactam. up to a maximum dose of 1.5 gFor pediatric patients with cUTI or cIAI weighing greater than 50 kg, do not exceed a maximum dose of 1.5 g.
Provides 1 g ceftolozane and 0.5 g tazobactam | Every 8 hours | 1 hour | 5 to 14 days
Complicated Urinary Tract Infections, IncludingPyelonephritis | ZERBAXA 30 mg/kg up to a maximum dose of 1.5 g | 1 hour | 7 to 14 days
Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia | Pediatric patients from at least 32 weeks of gestational age to less than 2 years | ZERBAXA 60 mg/kgProvides 40 mg/kg ceftolozane and 20 mg/kg tazobactam. up to a maximum dose of 3 gFor pediatric patients with HABP/VABP weighing greater than 40 kg, do not exceed a maximum dose of 3 g.
Provides 2 g ceftolozane and 1 g tazobactam. | 2 hours | 8 to 14 days
Pediatric patients from 2 years and older | ZERBAXA 75 mg/kgProvides 50 mg/kg ceftolozane and 25 mg/kg tazobactam. …
How to take Ceftolozane and Tazobactam — instructions & advice from the label
Serious Allergic Reactions
Advise patient that allergic reactions, including serious allergic reactions, could occur and that serious reactions require immediate treatment. Ask patient about any previous hypersensitivity reactions to ZERBAXA, other beta-lactams (including cephalosporins) or other allergens .
Potentially Serious Diarrhea
Advise patient that diarrhea is a common problem caused by antibacterial drugs. Sometimes, frequent watery or bloody diarrhea may occur and may be a sign of a more serious intestinal infection. If severe watery or bloody diarrhea develops, tell patient to contact his or her healthcare provider .
Antibacterial Resistance
Patients should be counseled that antibacterial drugs including ZERBAXA should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When ZERBAXA is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. …
Warnings & precautions
Do not take this medicine if: ZERBAXA is contraindicated in patients with known serious hypersensitivity to the components of ZERBAXA (ceftolozane and tazobactam), piperacillin/tazobactam, or other members of the beta-lactam class.
In a subgroup analysis of a Phase 3 cIAI trial of adult patients, clinical cure rates were lower in patients with baseline CrCl of 30 to 50 mL/min compared to those with CrCl greater than 50 mL/min (Table 6). The reduction in clinical cure rates was more marked in the ZERBAXA plus metronidazole arm compared to the meropenem arm. A similar trend was also seen in the cUTI trial. Monitor CrCl at least daily in patients with changing renal function and adjust the dosage of ZERBAXA accordingly .
Baseline Renal Function | ZERBAXA plus Metronidazolen/N (%) | Meropenemn/N (%)
CrCl greater than 50 mL/min | 312/366 (85.2) | 355/404 (87.9)
CrCl 30 to 50 mL/min | 11/23 (47.8) | 9/13 (69.2)
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterial drugs.
Before initiating therapy with ZERBAXA, make careful inquiry about previous hypersensitivity reactions to other cephalosporins, penicillins, or other beta-lactams. If this product is to be given to a patient with a cephalosporin, penicillin, or other beta-lactam allergy, exercise caution because cross sensitivity has been established. If an anaphylactic reaction to ZERBAXA occurs, discontinue the drug and institute appropriate therapy.
Clostridioides difficile-associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial agents, including ZERBAXA, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of C. difficile.
C. …
Ceftolozane and Tazobactam side effects
The following serious reactions are described in greater detail in the Warnings and Precautions section:
Hypersensitivity reactions
Clostridioides difficile-associated diarrhea
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and also may not reflect rates observed in practice.
Adult Patients
Complicated Intra-abdominal Infections and Complicated Urinary Tract Infections, Including Pyelonephritis
ZERBAXA was evaluated in Phase 3 comparator-controlled clinical trials of cIAI (Trial 1) and cUTI (Trial 2), which included a total of 1015 patients treated with ZERBAXA (1.5 g every 8 hours, adjusted based on renal function where appropriate) and 1032 patients treated with comparator (levofloxacin 750 mg daily in cUTI or meropenem 1 g every 8 hours in cIAI) for up to 14 days. The mean age of treated patients was 48 to 50 years (range 18 to 92 years), across treatment arms and indications. In both indications, about 25% of the subjects were 65 years of age or older. Most patients (75%) enrolled in the cUTI trial were female, and most patients (58%) enrolled in the cIAI trial were male. Most patients (>70%) in both trials were enrolled in Eastern Europe and were White.
The most common adverse reactions (5% or greater in either indication) occurring in patients receiving ZERBAXA were nausea, diarrhea, headache, and pyrexia. …
About this medicine
ZERBAXA (ceftolozane and tazobactam) is an antibacterial combination product consisting of the cephalosporin antibacterial drug ceftolozane sulfate and the beta-lactamase inhibitor tazobactam sodium for intravenous administration.
Ceftolozane sulfate is a semi-synthetic antibacterial drug of the beta-lactam class for parenteral administration. The chemical name of ceftolozane sulfate is 1H-Pyrazolium, 5-amino-4-[[[(2-aminoethyl)amino]carbonyl]amino]-2-[[(6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-,sulfate (1:1). The molecular formula is C23H31N12O8S2
+∙HSO4
- and the molecular weight is 764.77.
Figure 1: Chemical structure of ceftolozane sulfate
Tazobactam sodium, a derivative of the penicillin nucleus, is a penicillanic acid sulfone. Its chemical name is sodium (2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate-4,4-dioxide. The chemical formula is C10H11N4NaO5S and the molecular weight is 322.3. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 70ac1d90-eff3-4f0b-9f46-5846c571b32f. Read the full official label on DailyMed.
Related medicines
Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin